SO
NMRA icon

STRS Ohio’s Neumora Therapeutics NMRA Stock Holding History

STRS Ohio’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-600
Closed -$600 – 2275
2025
Q1 		$600 Hold
600
– – ﹤0.01% 1921
2024
Q4 		$6.36K Hold
600
– – ﹤0.01% 1858
2024
Q3 		$7.93K Hold
600
– – ﹤0.01% 1934
2024
Q2 		$5.9K Sell
600
-1,600
-73% -$16.6K ﹤0.01% 1931
2024
Q1 		$30K Sell
2,200
-1,000
-31% -$16.2K ﹤0.01% 1819
2023
Q4 		$54K Buy
+3,200
New +$39.3K ﹤0.01% 1766

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

STRS Ohio's NMRA Position: Q2 2025 in Review

STRS Ohio sold out of Neumora Therapeutics (NMRA) in Q2 2025, closing a stake of 600 shares — an estimated $600 sold.

STRS Ohio first reported a position in NMRA in Q4 2023 and held it in 6 quarters. The position peaked at $54K in Q4 2023. 98 funds tracked by Wall St. Rank hold NMRA as of Q2 2025.

  • STRS Ohio reported no remaining Neumora Therapeutics position as of Q2 2025 after selling out during the quarter.
  • STRS Ohio sold 600 Neumora Therapeutics shares in Q2 2025, an estimated $600.
  • STRS Ohio first reported a position in Neumora Therapeutics in Q4 2023 and held it in 6 quarters.
  • STRS Ohio's Neumora Therapeutics position peaked at $54K in Q4 2023.
  • 98 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2025.

Based on STRS Ohio's 13F filing for Q2 2025, filed 4 Aug 2025.